The impact of low-volume hydration on kidney function in low-dose cisplatin therapy for biliary tract cancer: a multicentre retrospective cohort study

Résumé fourni par la source

Hydration is crucial for preventing cisplatin-induced nephrotoxicity; however, optimal hydration for low-dose cisplatin (<50 mg/m2) remains unclear. This multicentre retrospective study assessed whether low-volume hydration (LV, <1500 mL) is non-inferior to high-volume hydration (HV, ≥1500 mL) in patients with biliary tract cancer receiving gemcitabine plus cisplatin (25 mg/m2). Of 239 patients, 109 LV and 97 HV patients were analysed. Primary endpoint was acute kidney injury (AKI) incidence. Propensity score weighting was applied to adjust for confounders. Post-adjustment AKI incidence was 4.7% (LV) vs. 10.1% (HV), confirming non-inferiority (risk difference upper 95% CI: 0.002, margin <0.05). No significant differences were observed in serum creatinine or creatinine clearance trajectories. In conclusion, low-volume hydration was non-inferior to high-volume hydration for AKI risk in low-dose cisplatin therapy. These findings support tailoring hydration to reduce patient burden without compromising safety.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.